Evidence map›Paper›PMID 42487019›Full record

ArticleEuropean journal of nuclear medicine and molecular imaging2026

Deciphering the phenotypic responses to

Marco Ranzani, Alessandro Cicconi, Guillermo Sastre-Moreno, Asmita Thapa, Elise Simon, Josefine Reber, Joseph Barlow, Marie Laure Boursier, Aurora Cerutti, Luisa Deberle and 17 more

Abstract read
PubMed Publisher
In one paragraph

Article in European journal of nuclear medicine and molecular imaging, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Marco Ranzani *Artios Pharma, Babraham Research Campus, Cambridge, UK.
Alessandro Cicconi *Artios Pharma, Babraham Research Campus, Cambridge, UK.
Guillermo Sastre-Moreno *Novartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Asmita ThapaArtios Pharma, Babraham Research Campus, Cambridge, UK.
Elise SimonNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Josefine ReberNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Joseph BarlowArtios Pharma, Babraham Research Campus, Cambridge, UK.
Marie Laure BoursierArtios Pharma, Babraham Research Campus, Cambridge, UK.
Aurora CeruttiArtios Pharma, Babraham Research Campus, Cambridge, UK.
Luisa DeberleNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Luigi Del PozzoNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Elias ElinatiArtios Pharma, Babraham Research Campus, Cambridge, UK.
Lerin GeoArtios Pharma, Babraham Research Campus, Cambridge, UK.
Vera GrinkevichArtios Pharma, Babraham Research Campus, Cambridge, UK.
Charlene HartnagelNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Sravanth K HindupurNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Katjusa KolerArtios Pharma, Babraham Research Campus, Cambridge, UK.
Suraj MenonArtios Pharma, Babraham Research Campus, Cambridge, UK.
Joana NevesArtios Pharma, Babraham Research Campus, Cambridge, UK.
Barbara SchacherNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Nan ShaoArtios Pharma, Babraham Research Campus, Cambridge, UK.
Eeson RajendraArtios Pharma, Babraham Research Campus, Cambridge, UK.
Markus ReschkeNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Tobias SchmelzleNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland.
Graeme C M SmithArtios Pharma, Babraham Research Campus, Cambridge, UK.
Helen M R RobinsonArtios Pharma, Babraham Research Campus, Cambridge, UK. hrobinson@artios.com.ORCID http://orcid.org/0000-0003-0414-0740
Marta Cortes-CrosNovartis Biomedical Research, Disease Area Oncology, Basel, Switzerland. marta.cortes-cros@novartis.com.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

purposeRadioligand therapy (RLT) delivers radionuclides, such as Lutetium-177 (

methodsDNA damage response (DDR) markers were profiled by immunofluorescence in cancer cell lines treated with DOTA-chelated

results[

conclusionThese results provide novel mechanistic insights into

Indexed as

LutetiumRadioisotopesAnimalsCell Line, TumorCell SurvivalDNA-Activated Protein KinaseDNA DamageHeterocyclic Compounds, 1-RingHumansLigandsMaleMicePhenotypeDNA-Activated Protein KinaseHeterocyclic Compounds, 1-RingLigandsLutetiumLutetium-177Radioisotopes[177Lu]Lu-PSMA-617DNA damage responseDNA-PK inhibitorDouble-strand break repairNon-homologous end joiningRadioligand therapy

Identifiers

PMID42487019

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.